Sugi Predict

Sugi Predict / Compounds / SCHEMBL1353609

SCHEMBL1353609

SCHEMBL1353609

Cc1nc(-c2ccc(N)cc2)no1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.62
▸ CA1 P00915 2/20 0.62
▸ CA2 P00918 2/20 0.62
▸ CA9 Q16790 2/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ PLK1 P53350 1/20 0.56
▸ MAOA P21397 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ ACHE P22303 2/20 0.52
▸ RAB9A P51151 4/20 0.50
▸ LMNA P02545 2/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ NFKB2 Q00653 2/20 0.50
▸ RELA Q04206 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ AOC3 Q16853 2/20 0.47
▸ SMYD3 Q9H7B4 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ MPO P05164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415301 0.89 L3MBTL1 (0.69) CA12CA1CA2CA9L3MBTL1
SCHEMBL8457708 0.84 L3MBTL1 (0.54) CA12CA1CA2CA9L3MBTL1
SCHEMBL2967349 0.83 L3MBTL1 (0.62) CA12CA1CA2CA9L3MBTL1
SCHEMBL10022409 0.81 L3MBTL1 (0.55) CA12CA1CA2CA9L3MBTL1
SCHEMBL19941493 0.80 CA12 (0.54) CA12CA1CA2CA9L3MBTL1
SCHEMBL13621955 0.80 L3MBTL1 (0.58) CA12CA1CA2CA9L3MBTL1
SCHEMBL1170085 0.80 NR1H4 (0.59) CA12CA1CA2CA9L3MBTL1
SCHEMBL753304 0.80 L3MBTL1 (0.58) CA12CA1CA2CA9L3MBTL1
SCHEMBL2359857 0.80 NR1H4 (0.66) CA12CA1CA2CA9L3MBTL1
SCHEMBL1128734 0.80 PLK1 (0.60) CA12CA1CA2CA9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545654-B2 MYC inhibitors and uses thereof STEMSYNERGY THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. 2023-05-18 — — US disclosed
EP-4103188-A1 MYC INHIBITORS AND USES THEREOF StemSynergy Therapeutics, Inc. (US) 2022-12-21 — — EP disclosed
WO-2021163192-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. (US) 2021-08-19 — — WO disclosed
WO-2021163192-A1 MYC INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. (US) 2021-08-19 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 — — US disclosed
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 — — US disclosed
EP-1095025-B1 BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2002-12-11 — — EP disclosed
US-6451832-B2 E.G., 2-(AMINDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(ETHOXY-CARBONYL-METHYLAMINO)-1 -(2,5-DIHYDROPYRROLOCARBONYL)-ETHYL)BENZIMIDAZOLE; ANTICOAGULANTS AND ANTITHROMBOLYTIC AGENTS BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-09-17 — — US disclosed
US-20010006977-A1 Benzimidazoles with antithrombotic activity BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2001-07-05 — — US disclosed
US-6248770-B1 CARDIOVASCULAR DISORDERS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-06-19 — — US disclosed
EP-1056743-A1 BENZAMINE DERIVATIVES MERCK PATENT GmbH (DE) 2000-12-06 — — EP disclosed
EP-0975593-A1 INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2000-02-02 — — EP disclosed
WO-1999031092-A1 BENZAMINE DERIVATIVES MERCK PATENT GMBH (DE) 1999-06-24 — — WO disclosed
WO-1998050358-A1 INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1998-11-12 — — WO disclosed
US-5627197-A Adhesion receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1997-05-06 — — US disclosed
EP-0727425-A1 Adhesion receptor antagonists MERCK PATENT GmbH (DE) 1996-08-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150956-A1 MYC INHIBITORS AND USES THEREOF MYC, AURKA, AURKC CA12 4348/4885CA1 4533/4885CA2 4188/4885
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES HPSE, GAA, MAN2B1 CA12 2097/4885CA1 2896/4885CA2 2540/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CA12 4853/4885CA1 4820/4885CA2 3360/4885
US-20010006977-A1 Benzimidazoles with antithrombotic activity SERPINC1, SERPINB1, PF4 CA12 4708/4885CA1 4471/4885CA2 3561/4885
US-12545654-B2 MYC inhibitors and uses thereof MYC, MYCBP, NR2E1 CA12 3943/4885CA1 2291/4885CA2 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.